A pharmacokinetic evaluation of topotecan as a cervical cancer therapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 2, 2013, Pages 215-224

  Musa, Fernanda ^a   Blank, Stephanie ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Locally advanced cervical cancer; Metastatic cervical cancer; Neoadjuvant chemotherapy; Persistent cervical cancer; Radiosensitizer; Recurrent cervical cancer; Topotecan

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; OXALIPLATIN; PACLITAXEL; TEMSIROLIMUS; TOPOTECAN; VELIPARIB;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ASTHENIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DNA DAMAGE; DNA REPLICATION; DRUG BINDING; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DYSPNEA; HUMAN; INFECTION; LEUKOPENIA; LUNG EMBOLISM; METASTASIS; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; RECTUM HEMORRHAGE; REVIEW; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; TOPOISOMERASE I INHIBITORS; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 84872469461     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.758249     Document Type: Review

References (49)

1. Cancer Statistics. 2010.Available from: http:http://www. cancer.org
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518-27
3. Green JA. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer: a meta-analysis. Clin Oncol (R Coll Radiol) 2004;16(1):82 (Pubitemid 38195879)
4. Houvenaeghel G, Lelievre L, Gonzague-Casabianca L, et al. Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecol Oncol 2006;100(2):338-43 (Pubitemid 43075266)
5. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005;23(21):4626-33 (Pubitemid 46224065)
6. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22(15):3113-19 (Pubitemid 41103724)
7. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27(28):4649-55
8. Fiorica JV, Blessing JA, Puneky LV, et al. A phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2009;115(2):285-9
9. NCI Clinical Announcement on Cervical Cancer: chemotherapy plus Radiation Improves Survival. Available from: http://www.cancer.gov/newscenter/ newsfromnci/1999/cervicalcancer . Clinical alert that established the role of chemoradiation in cervical cancer. 10. A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone. Available from: http://www.rtog.org/LinkClick.aspx? fileticket=MI6h0alB0AY%3D&tabid=290
10. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005(3):CD002225
11. Duenas-Gonzalez A, Zarba JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011;29(13):1678-85
12. Park SR, Chen A. Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am 2012;26(3):649-70, ix 14. Drugs@FDA: Topotecan
13. Moukharskaya J, Verschraegen C. Topoisomerase 1 inhibitors and cancer therapy. Hematol Oncol Clin North Am 2012;26(3):507-25; vii
14. Zhang H, D'Arpa P, Liu LF. A model for tumor cell killing by topoisomerase poisons. Cancer Cells 1990;2(1):23-7
15. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-75 (Pubitemid 19172974)
16. Capranico G, Zunino F. DNA topoisomerase-trapping antitumour drugs. Eur J Cancer 1992;28A(12):2055-60
17. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973;33(11):2834-6
18. Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;34(1):98-107
19. Sanghavi SN, Needle MN, Krailo MD, et al. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952. Neuro-oncol 2003;5(1):8-13
20. Rapisarda A, Uranchimeg B, Sordet O, et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64(4):1475-82 (Pubitemid 38235619)
21. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007;26(2):341-52 (Pubitemid 47101663)
22. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62(15):4316-24 (Pubitemid 34827288)
23. Rapisarda A, Zalek J, Hollingshead M, et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004;64(19):6845-8 (Pubitemid 39330988)
24. Staker BL, Hjerrild K, Feese MD, et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 2002;99(24):15387-92 (Pubitemid 35403944)
25. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 1994;20(1):73-96 (Pubitemid 24043771)
26. Schutte W, Manegold C, von Pawel JV, et al. Topotecan-a new treatment option in the therapy of brain metastases of lung cancer. Front Radiat Ther Oncol 1999;33:354-63
27. van Warmerdam LJ, Rodenhuis S, van der Wall E, et al. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 1996;73(8):979-84 (Pubitemid 26116752)
28. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998;34(10):1500-8 (Pubitemid 28446329)
29. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12(3):553-9 (Pubitemid 24079898)
30. Hochster H, Wadler S, Runowicz C, et al. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol 1999;17(8):2553-61 (Pubitemid 29368258)
31. Schellens JH, Creemers GJ, Beijnen JH, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996;73(10):1268-71 (Pubitemid 26162345)
32. Muggia FM, Hudes GR. Boosting bioavailability to topotecan: what do we gain? J Clin Oncol 2003;21(1):177
33. Mould DR, Holford NH, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002;71(5):334-48 (Pubitemid 34518144)
34. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15(6):2183-93 (Pubitemid 27251118)
35. Manci N, Marchetti C, Di Tucci C, et al. A prospective phase II study of topotecan (Hycamtin(R)) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol 2011;122(2):285-90
36. Zanaboni F. Weekly topotecan and cisplatin as neo-adjuvant chemotherapy for locally advanced squamous cervical carcinoma: preliminary results of a phase II multicentric study. European Society of Gynecologic Oncology (ESGO); Milan, Italy; 2011.
37. Hall EJ. Radiobiology for the radiologist. 5 edition. Lippincott Williams Wilkins, Philadelphia; 2000.
38. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;34:191-218
39. Lorusso D, Pietragalla A, Mainenti S, et al. Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol 2010;74(3):163-74
40. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001;358(9284):781-6 (Pubitemid 32868726)
41. Fiorica J, Holloway R, Ndubisi B, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol 2002;85:89-94 (Pubitemid 34304015)
42. Bell MC, Davidson SA, Mathis JM, Ampil F. Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial. Gynecol Oncol 2001;80(2):128-31 (Pubitemid 32158448)
43. Dunton CJ, King SA, Neufeld J, et al. Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecol Oncol 2002;85(1):185-7 Available from: clinicaltrials.gov \ (Pubitemid 34304032)
44. Rose PG, Sill MW, McMeekin DS, et al. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol 2012;125(1):158-62
45. Tiersten AD, Selleck MJ, Hershman DL, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 2004;92(2):635-8 (Pubitemid 38183155)
46. Burris HA III, Infante JR, Jewell RC, et al. A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies. Oncologist 2010;15(9):954-60
47. Kurtz JE, Hardy-Bessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol 2009;113(1):16-20
48. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010;117(3):473-6
49. Coronel J, Cetina L, Pacheco I, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 2011;28(Suppl 1):S540-6